Amgen 3Q Revenues: $5.0 billion (+6%) 3Q Earnings: $1.2 billion (-9%) YTD Revenues: $14.7 billion (+8%) YTD Earnings: $3.9 billion(-5%) Comments:  Kyprolis sales in the quarter were $94 million, a 21% increase from 2Q14. Prolia sales increased 43% to $255 million. Neulasta sales increased 5% to $1.2 billion. NEUPOGEN sales decreased 36% mainly due to a $155 million order from the U.S. government in the quarter. XGEVA sales were $318 million, up 22%. Vectibix sales increased 29% to $138 mill...